FASLODEX® (fulvestrant) Injection for intramuscular administration is an estrogen receptor antagonist without known agonist effects. The chemical name is 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol.
FASLODEX is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Media Articles Related to Faslodex (Fulvestrant)
High vitamin D levels may increase breast cancer survival
Source: Health News from Medical News Today [2014.03.07]
Past studies have claimed that vitamin D may reduce the risk of heart disease, bone fractures and even depression. Now, new research suggests that breast cancer patients with high levels of the vitamin in their blood are twice as likely to survive the disease than patients with low levels.The researchers, led by Prof. Cedric F. Garland of the University of California, San Diego School of Medicine, recently published their findings in the journal Anticancer Research.
Imprint of chemotherapy linked to inflammation in breast cancer survivors
Source: Breast Cancer News From Medical News Today [2014.03.06]
Many breast cancer survivors experience fatigue and other debilitating symptoms that persist months to years after their course of treatment has ended.Now researchers at the Winship Cancer Institute of Emory University have found clues that may explain how these symptoms can linger.
OncoBriefs: Melanoma Drugs, Vitamin D and Breast Cancer
Source: MedPage Today Dermatology [2014.03.06]
(MedPage Today) -- Encouraging data from a preliminary trial of a novel therapy for melanoma lead off summaries of recent oncology-related research.
Yoga 'improves quality of life' for breast cancer patients
Source: Breast Cancer News From Medical News Today [2014.03.04]
Radiation therapy is one of the main treatments for cancer, and one of the most common side effects of the treatment is fatigue. But new research from the University of Texas MD Anderson Cancer Center suggests that for breast cancer patients undergoing radiation therapy, yoga may combat this side effect by regulating stress hormones, improving quality of life beyond treatment.
Breast cancer spread may be reduced by silencing a gene
Source: Breast Cancer News From Medical News Today [2014.03.03]
Myoferlin, a protein only recently linked to cancer, may help breast cancer cells transform so they can escape tumors and migrate to new sites. When researchers implanted mice with breast cancer cells that couldn't make the protein because its gene was switched off, the cells did not transform into the type that migrates.
Published Studies Related to Faslodex (Fulvestrant)
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. [2011.01]
BACKGROUND AND PURPOSE: Fulvestrant, an oestrogen receptor (ER) antagonist with no known agonist effects, has shown activity in postmenopausal patients with ER-positive advanced breast cancer recurring or progressing following prior endocrine therapy. This double-blind, double-dummy, randomised phase III study (NCT00327769) was designed to compare the efficacy and safety of fulvestrant versus anastrozole in advanced breast cancer of Chinese postmenopausal women whose disease has progressed following prior endocrine treatment... CONCLUSIONS: These data demonstrate that fulvestrant 250 mg and anastrozole were similarly effective and well tolerated in the treatment of postmenopausal Chinese women with advanced breast cancer whose disease had progressed or recurred on prior endocrine treatment.
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast
cancer: results of a multicentre, double-blind, randomised phase III trial. 
whose disease has progressed following prior endocrine treatment... CONCLUSIONS: These data demonstrate that fulvestrant 250 mg and anastrozole were
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). [2010.12]
BACKGROUND: FINDER1 compared efficacy, tolerability and pharmacokinetics (PK) of three fulvestrant dose regimens in postmenopausal Japanese women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer recurring or progressing after prior endocrine therapy... CONCLUSION: Fulvestrant AD, LD and HD had similar efficacy and tolerability profiles in postmenopausal Japanese women with ER-positive advanced breast cancer.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. [2010.10.20]
PURPOSE: We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy... CONCLUSION: Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity, corresponding to a clinically meaningful improvement in benefit versus risk compared with fulvestrant 250 mg.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with
fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive
advanced breast cancer. 
endocrine therapy... CONCLUSION: Fulvestrant 500 mg was associated with a statistically significant
Clinical Trials Related to Faslodex (Fulvestrant)
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer [Completed]
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast
cancer treatment and assess the relationship between dose, exposure, degree of reduction in
tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. [Active, not recruiting]
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant
with the standard dose of 250 mg in postmenopausal women with estrogen receptor positive
advanced breast cancer who have failed on a previous endocrine treatment.
Faslodex and Herceptin, Alone and Combined [Recruiting]
The purpose of this study is to evaluate the the relative anti-tumor efficacy of combined Faslodex and Herceptin therapy as compared with that of Faslodex or Herceptin given alone for first-line treatment in patients with metastatic breast cancer.
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
(exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
Patients will be treated until disease progression or until the investigator has determined
that treatment is not in the best interest of the patient, whichever occurs first.
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor [Recruiting]
The purpose of this study is to find out what effect the combination of fulvestrant
(Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant
Reports of Suspected Faslodex (Fulvestrant) Side Effects
Injection Site Pain (21),
Back Pain (17),
Pain in Extremity (15),
Disease Progression (14),
Hot Flush (13), more >>